Skip to main content
Finanzoo GmbH Finanzoo GmbH

Cytokinetics Value Stock - Dividend - Research Selection

Cytokinetics

ISIN: US23282W6057 , WKN: A1W1KK
Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company\'s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


Cytokinetics, Incorporated (CYTK): A Bull Case Theory

2026-02-04
We came across a bullish thesis on Cytokinetics, Incorporated on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls’ thesis on CYTK. Cytokinetics, Incorporated’s share was trading at $65.16 as of February 2nd. Cytokinetics (CYTK) is a late-stage biopharma focused on developing drugs that target the sarcomere, specifically cardiac myosin, to treat debilitating muscle diseases. Its pipeline […]
Yahoo

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates

2026-01-30
Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo

Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM

2026-01-28
Cytokinetics (CYTK), Incorporated announced the launch of “On Track with HCM,” demonstrating the company’s long-standing commitment to the, Hypertrophic Cardiomyopathy, HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy, HCM, for more than two decades before receiving a heart transplant. Claim 50% Off TipRank
Yahoo

Halozyme buys a biotech startup; Cytokinetics launches heart drug

2026-01-28
Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst wrote. Elsewhere, Boehringer dipped into China for a bispecific drug and a trans-Atlantic VC firm restocked.
Yahoo

Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum

2026-01-28
Recent performance snapshot for Cytokinetics (CYTK) Cytokinetics (CYTK) has drawn investor attention recently, with the stock last closing at US$64.01 and showing positive total returns over the past year, the past 3 months, and the past 5 years. See our latest analysis for Cytokinetics. For context, the share price has been edging higher. A 30 day share price return of 1.43% is feeding into a 3.69% year to date gain, while the 1 year total shareholder return of 31.44% and 5 year total...
Yahoo

How MYQORZO’s REMS‑Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors

2026-01-27
Cytokinetics recently announced that MYQORZO (aficamten), a cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, is now commercially available in the U.S. via a restricted FDA Risk Evaluation and Mitigation Strategy program. Beyond launch, the company is rolling out the MYQORZO & You support program and a specialty pharmacy network, underlining a strong focus on structured access, monitoring and patient education around this newly approved...
Yahoo

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

2026-01-27
“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of “On Track with HCM,” demonstrating the company’s long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her f
Yahoo

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

2026-01-27
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. MYQORZO was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic obstructive hypertrophic ca
Yahoo

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-01-20
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 29,416 shares of common stock and 19,825 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees, whose employment commenced in December 2025 and January 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of th
Yahoo

CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten)

2026-01-12
NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.1 “MYQORZO represents a meaningful advancement for adults living with obstructive hypertrophic cardiomyopathy, and we are extremely excited to partner closely with the team
Yahoo